Houdini Bio launches to solve therapeutic and commercial bottlenecks of genetic medicines
Houdini Bio today announced its official launch, having surpassed key milestones supported by approximately £1.5 million in non-dilutive grant funding and capital from an oversubscribed pre-seed round led by SCVC (the venture arm of Science Creates), with participation from Deep Science Ventures and the University of Cambridge (Cambridge Enterprise VC). The combined funding enabled Houdini Bio to rapidly validate its technology and achieve projected technical milestones in a third of the predicted time. The platform- a machine learning-guided DNA sequence design infrastructure- is engineered to overcome the biological barriers limiting genetic medicines. Positioned for rapid commercial scaling ahead of its next funding round, Houdini Bio provides the infrastructure required to make genetic medicines work durably, consistently and cost-efficiently at scale- transforming outcomes for patients suffering from blindness, cystic fibrosis, haemophilia, dementia, cancer and more.
While gene and cell therapies are progressing rapidly, their real-world impact is held back by a fundamental biological hurdle: the human cell often mistakes therapeutic DNA for a viral invader. To protect itself, the cell triggers natural defenses that ‘silence’ the medicine. This premature shutdown limits the treatment's long term effectiveness, drives up manufacturing costs and demands high doses which can cause dangerous immune reactions in patients. Current industry attempts to keep these therapies active rely on trial-and-error experimentation, which is slow, costly and unreliable.
Houdini Bio solves this problem at the level of the genetic code itself. By combining machine learning with a deep understanding of cellular defenses- specifically a master silencing mechanism known as the Human Silencing Hub (HUSH) complex- Houdini Bio has created a toolkit to re-engineer therapeutic DNA. This approach gives the medicine a genetic camouflage, preserving its medical purpose while making it invisible to the cell's defenses. The platform uses advanced sequence design to reliably boost gene expression output by more than 10-fold compared to current state-of-the-art methods, ensuring therapies work more efficiently, at lower doses, for longer.
The company's foundational science bridges academic discovery and industrial application. The HUSH complex was originally discovered by Professor Paul Lehner at the University of Cambridge, who identified how the body silences foreign genetic material. Building on this breakthrough during his PhD in molecular genetics, Houdini Bio CEO Jonathan Cohen-Gold discovered a novel set of molecular rules that allow certain DNA sequences to escape this cellular lock-down. Houdini Bio has accelerated these insights using AI, building an engineering platform that paves the way for more affordable, durable gene therapies and cell therapies like CAR-T.
Jonathan Cohen-Gold, CEO and Co-Founder of Houdini Bio said:
The industry has made incredible strides, proving genetic medicines can cure previously untreatable diseases, but cellular machinery still rejects these therapies, limiting long term effectiveness and forcing costly, unsafe doses. Our platform introduces a vital shift from trial-and-error screening to repeatable, engineering-driven DNA design. By discovering the molecular rules which allow sequences to escape HUSH, we can rewrite therapeutic DNA to clear cellular checkpoints. We are providing the missing link between these incredible medicines, the market and the patients who need them.”
To drive its commercial strategy, Cohen-Gold is joined by co-founder and Chief Business Officer Lee Dunham. Having worked with more than 100 cell and gene therapy companies over the past decade- including as a Director of Business Development at Cell and Gene Therapy Catapult- Dunham has seen firsthand why promising therapies stall, founding Houdini Bio after recognising its unique ability to solve a huge industry challenge.
Harry Destecroix, Founder and Managing Partner of SCVC said:
Gene therapies really do represent the future of medicine, but they are stuck behind an invisible commercial and biological bottleneck. Houdini Bio represents the exact type of deep tech infrastructure the ecosystem needs. Solving DNA silencing at the biological root transforms long term efficacy and unit economics, revolutionising the commercial and treatment benefits of gene and cell therapies alike. We are thrilled to back a skilled, ambitious team turning complex biology into a truly usable and scalable solution.
Tom Payne, Chief Operating Officer of Laverock Therapeutics and Houdini Bio advisor said:
Translating the discovery of the HUSH complex into a predictive engineering toolkit is a massive leap forward for translational biology. Houdini Bio’s ability to decipher the rules and mechanisms of HUSH and apply them to synthetic biology resolves a multi-decade challenge in molecular medicine, allowing transgenes to predictably escape host repression for the first time.
With its platform fully validated ahead of schedule, the company will maintain momentum to expand its team and scale co-development partnerships with pharma companies, deep tech innovators and pioneering developers looking to integrate anti-silencing technology into next-generation drug pipelines.
